Dandekar Atul 4

What Happened
Atul Dandekar, Chief Strategy & Business Officer (CSBO) of Maze Therapeutics, exercised stock options on May 4, 2026 to acquire a total of 14,305 shares (8,320 + 5,985). The exercise price was $10.42 per share, for a cash outlay of approximately $149,058. The filing shows the corresponding option interests were surrendered (derivative reported disposed at $0), and no immediate sale of the acquired shares was reported.

Key Details

• Transaction date: May 4, 2026. Form 4 filed May 6, 2026 (timely).
• Exercise price: $10.42 per share; shares acquired: 14,305; total paid ≈ $149,058.
• Transaction code: M (exercise/conversion of derivative). Derivative "disposed" entries at $0 reflect surrender/conversion of the options upon exercise.
• Shares owned after the transaction: not specified in the provided filing detail.
• Footnotes: F1 — option was fully vested (became fully vested Feb 1, 2026). F2 — original award vested monthly at 1/48th starting Apr 1, 2023 (standard multi-year vesting schedule).

Context
This was an option exercise (the insider paid cash to convert vested options into common shares), not a sale. Exercises are routine for insiders holding equity awards; they increase the insider’s share ownership but don’t by themselves signal intent to buy or sell on the open market. The filing indicates the options were fully vested prior to exercise.